Showing results (171-180 of 215) with videos related to
Sort By:
Pageof 22
Cancer Research|October 17, 2020
A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System LymphomaKensuke Tateishi, Yohei Miyake, Masahito Kawazu, et al.Nature Communications|October 13, 2021
Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastasesSanjay M Prakadan, Christopher A Alvarez-Breckenridge, Samuel C Markson, et al.Cell|September 18, 2018
Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in GliomaSamuel K McBrayer, Jared R Mayers, Gabriel J DiNatale, et al.Neuro-Oncology|November 4, 2024
Development and validation of a clinical risk model for postoperative outcome in newly diagnosed glioblastoma: A report of the RANO resect groupPhilipp Karschnia, Jacob S Young, Gilbert C Youssef, et al.Nature Medicine|June 20, 2020
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosisPriscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2019
PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial TumorsKensuke Tateishi, Taishi Nakamura, Tareq A Juratli, et al.Nature Medicine|January 16, 2026
Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trialPriscilla K Brastianos, Katharine Dooley, Susan Geyer, et al.Neuro-Oncology Advances|February 6, 2025
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomesTyler A Lanman, Gilbert Youssef, Raymond Huang, et al.Nature Medicine|June 2, 2023
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial resultsPriscilla K Brastianos, Albert E Kim, Anita Giobbie-Hurder, et al.Nature Communications|October 13, 2021
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosisPriscilla K Brastianos, Matthew R Strickland, Eudocia Quant Lee, et al.Pageof 22